Skip to main content

GBS, Inc. (GBS)

NASDAQ: GBS · IEX Real-Time Price · USD
2.08
+0.03 (1.46%)
After-hours:Oct 22, 2021 7:07 PM EDT
2.05
-0.10 (-4.65%)
At close: Oct 22, 4:00 PM
Market Cap30.51M
Revenue (ttm)1.98M
Net Income (ttm)-7.04M
Shares Out10.41M
EPS (ttm)-0.68
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume544,775
Open2.15
Previous Close2.15
Day's Range1.94 - 2.19
52-Week Range1.94 - 14.24
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 11, 2021

About GBS

GBS Inc. operates as a biosensor diagnostic technology company. It offers Saliva Glucose Biosensor that uses saliva to measure glucose non-invasively. The company also focuses on developing COV2 test, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumour markers, hormones, and nucleic acid diagnostic modalities. It has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The...

IndustryMedical Devices
IPO DateDec 23, 2020
Employees7
Stock ExchangeNASDAQ
Ticker SymbolGBS
Full Company Profile

Financial Performance

In 2021, GBS, Inc.'s revenue was $1.98 million, an increase of 949.30% compared to the previous year's $188,744. Losses were -$7.04 million, 122.4% more than in 2020.

Financial Statements

News

FDA Pre-Submission for Saliva-Based Glucose Test to Replace Invasive Finger-Prick

SYDNEY, Oct. 19, 2021 /PRNewswire/ -- The iQ Group Global Ltd (NSX.IQG), on behalf of its subsidiary, Life Science Biosensor Diagnostics Pty Ltd (LSBD), is pleased to announce that one of its licensees,...

4 days ago - PRNewsWire

GBS Inc. Announces its Pre-Submission package is with the FDA

NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at p...

1 week ago - GlobeNewsWire

GBS Inc. to Present at Upcoming September Virtual Investor Conferences

H.C. Wainwright 23 rd Global Investor Conference: September 13 th - 15 th

1 month ago - GlobeNewsWire

Life Sciences Company GBS Develops Technology to Take the Fear out of Diabetes and COVID Testing

GBS Inc. is presenting at the Benzinga Healthcare Small Cap Conference on September 29, 2021. For some people with diabetes, testing with a pinprick is no more than a minor inconvenience.

2 months ago - Benzinga

GBS Awarded $4.7 Million Australian Federal Government Science Grant To Manufacture Biosensor Technology

NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-...

3 months ago - GlobeNewsWire

Hot Penny Stocks to Buy Under $5? 3 You Might Not Have Heard Of

Looking for penny stocks under $5? Check these 3 out The post Hot Penny Stocks to Buy Under $5?

Other symbols:PROGRIG
4 months ago - PennyStocks

Patients Living With Diabetes Voice Eagerness for ‘Finger-Prick' Alternative in Global Glucose Monitoring Survey

Global results show 90% of patients are in favor of a saliva-based glucose test Global results show 90% of patients are in favor of a saliva-based glucose test

4 months ago - GlobeNewsWire

GBS Inc. Reports First Quarter 2021 Financial Results and Recent Business Highlights

- Anticipate Emergency Use Submission for SARS-CoV-2 Antibody Biosensor Test in the Second Half of 2021-

5 months ago - GlobeNewsWire

GBS, Inc. Receives Approval to Commence Validation Clinical Study for Rapid SARS-CoV-2 Diagnostic Test

NEW YORK, April 15, 2021 (GLOBE NEWSWIRE) -- GBS, Inc. (NasdaqGS: GBS), a life sciences company developing non-invasive, real-time point-of-care (POC) diagnostic tests, and the Wyss Institute for Biolog...

6 months ago - GlobeNewsWire

GBS Inc. Enters Sponsored Research Agreement with Johns Hopkins Bloomberg School of Public Health To Accelerate Devel...

NEW YORK, Feb. 18, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company that develops non-invasive, real-time point of care (POC) diagnostic tests for patients and their primary heal...

8 months ago - GlobeNewsWire

GBS, Inc. Announces Closing of Upsized $21.6 Million Initial Public Offering

NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) -- GBS Inc. (the “Company”) (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing in the hands of patients and their prima...

9 months ago - GlobeNewsWire

2 More IPOs Make Their Trading Debuts Today

GBS and Inhibikase Therapeutics priced late Tuesday.

Other symbols:IKT
10 months ago - Barrons

UPDATE - GBS Inc. Announces Pricing of $21.6 Million Initial Public Offering

Will Trade on the Nasdaq Global Market Under Ticker “GBS” Will Trade on the Nasdaq Global Market Under Ticker “GBS”

10 months ago - GlobeNewsWire

GBS Inc. Announces Pricing of Initial Public Offering

Will Trade on the Nasdaq Global Market Under Ticker “GBS”

10 months ago - GlobeNewswire

Saliva-based glucose device developer GBS lowers deal size by 10% ahead of $18 million IPO

GBS, which is developing saliva-based tests for SARS-CoV-2 and diabetes management in China, lowered the proposed deal size for its upcoming IPO on Tuesday. The New York, NY-based company now plans to r...

10 months ago - NASDAQ